Global Ischemic Heart Disease Drugs Market Research Report and Forecast 2021-2026
© 2019 IMARC All Rights Reserved
Author: Elena Anderson, Marketing Manager | Copyright © IMARC Service Pvt Ltd. All Rights Reserved IMARC Group
About IMARC Group
Report Description
The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
Report Description and Highlights
Report Description
Global Ischemic Heart Disease Drugs Market Outlook 2026: According to the latest report by IMARC Group, titled “ Ischemic Heart Disease (IHD) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity a nd Forecast 2021-2026 ”, the global Ischemic Heart Disease (IHD) drugs market is currently witnessing steady growth. Ischemic heart disease, also known as coronary heart (CHD) or coronary artery disease, refers to a heart problem in which the blood flow to the heart is restricted or reduced. This is caused by clogged arteries that supply less blood and oxygen to the heart muscles, eventually leading to a cardiac attack. The diverse pharmacological actions of various IHD drugs, such as calcium channel blockers, inhibit the influx of calcium ions into the myocardium and vascular smooth muscle tissues. The relaxation of the coronary artery due to calcium channel blocker therapy improves coronary blood flow, thereby increasing myocardial oxygen supply. The anti-ischemic effects of these drugs are often notable, especially the newer agents like amlodipine. Request for a free sample report: https://www.imarcgroup.com/ischemic-heart-disease-market/requestsample
Report Description and Highlights
Report Description
Global Ischemic Heart Disease Drugs Market Trends: In recent years, the increasing prevalence of heart diseases, along with the growing population of older adults who are more prone to heart ailments, has led to the rising demand for IHD drugs. Moreover, IHD drugs are incorporated in various cardiological treatment procedures, such as angioplasty, atherectomy and balloon angioplasty, for preventing relapse and ensuring healthy recovery, which has led to a consistent requirement for these drugs. Besides this, the high alcohol consumption, excessive smoking, reduced blood pressure control and lower physical activity are the factors that have increased the mortality rate from cardiovascular disease, which in turn is leading to a rise in the demand for IHD drugs across the globe. Moreover, several pharmaceutical companies are investing in the development of more advanced IHD drugs.
Report Description Report Description and Highlights Market Summary: Breakup by Disease Class • Angina Pectoris • Myocardial Infarction Breakup by Drug Class: • Anti-Dyslipidemic Drugs • Calcium Channel Blockers • Beta-Blockers • ACE Inhibitors • ARBs • Vasodilators • Antithrombotic Agents
Report Description Report Description and Highlights Breakup by Region: • North America • Europe • Asia Pacific • Middle East and Africa • Latin America On account of the aforementioned factors, the market is anticipated to witness strong growth during 2021-2026.
Report Description Report Description and Highlights Competitive Landscape With Keyplayer: • Bayer AG • Eli Lilly and Company • Novartis International AG • Pfizer Inc. • Sanofi S.A. • Actelion Pharmaceuticals Ltd. • Baxter International Inc. • Boehringer Ingelheim International GmbH • Bristol-Myers Squibb Company • Amgen Inc. • F. Hoffmann-La Roche AG • GlaxoSmithKline Plc • Merck & Co. • Eisai Co. Ltd. View Report TOC, Figures and Tables: https://www.imarcgroup.com/ischemic-heart-disease-market
A partial List of
We are the trusted business partners to the
Clients world's leading corporates, governments, and ourPartial ClientsList of institutions
A partial List of
We are the trusted business partners to the
of Clients leading corporates, governments, and ourPartial ClientsListworld's institutions
Report Description and Highlights
Report Description
© 2019 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
Contact Us
FOR MORE DETAILS Visit us at :
https://www.imarcgroup.com Stay With Us:
TELEPHONE: +1-631-791-1145 E-MAIL: sales@imarcgroup.com